Abstract
Background: Chronic infection with HCV can rapidly progress to cirrhosis leading to increased mortality rates in immunosuppressed organ-transplanted patients. In liver-transplanted patients, the introduction of directly acting antivirals has modified HCV natural history by providing a safe and effective therapy for this group of patients. To date there are no data on safety and efficacy of IFN-free regimens in HCV patients who received lung transplant (LuT). Methods: We report three patients who have received anti-HCV treatment after LuT with Sofosbuvir-based regimens. Results: All patients achieved a SVR, no unexpected safety signals were observed and no modifications in immunosuppressants were required. Conclusions: Our report is the first to show that HCV patients who underwent LuT can be safely treated with IFN-free regimens, thus opening the door for refined clinical management of this category of patients.
Original language | English |
---|---|
Pages (from-to) | 1585-1589 |
Number of pages | 5 |
Journal | Liver International |
Volume | 36 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 1 2016 |
Keywords
- direct acting antivirals
- hepatitis C virus
- immunosuppression
- lung transplant
- sofosbuvir
ASJC Scopus subject areas
- Hepatology